Breast Cancer

A first patient received samuraciclib plus Orserdu in a phase 2 trial, a treatment combination for some patients with HR-positive, HER2-negative metastatic breast cancer.

Sometimes, it is better to keep things to yourself when it comes to cancer.

An expert explained how next-generation sequencing can help patients with metastatic breast cancer understand their disease and available treatment options.

I found comfort and peace on social media from different cancer communities.

Who knew how impactful socks could be!

As Georgetown women’s basketball couch Tasha Butts died from cancer and “The Walking Dead” actor Erik Jensen revealed cancer diagnosis, here is what’s happening in the oncology space this week.

Breast cancer survivors may experience medium to high symptom burden five or more years after receiving a diagnosis, according to a recent study.

Dr. Noor Abuhadra and patient Shay Elkins discuss overcoming barriers to cancer treatment access and reimbursement. Shay shares her relatively smooth experience with insurance coverage, while Dr. Abuhadra emphasizes that healthcare teams will fight for patient coverage, especially when treatments are backed by research and FDA approval. Dr. Abuhadra also mentions having a financial clearance department to handle denials and secure approvals, as well as training staff to fill out prior authorization forms. Shay underlines the importance of self-advocacy and leveraging online communities for both emotional support and practical advice.

After the fear of my cancer diagnosis subsided, I decided to swing at it with all my strength.

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.

In a recent study, obesity was linked to an increased risk of recurrence for patients with HR-positive, early-stage breast cancer.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

Cancer forced me to face my mortality — and in doing so, I crafted a bucket list and embraced the true meaning of life.

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

Some patients with breast cancer who took Verzenio plus endocrine therapy two years after initial treatment demonstrated improved efficacy.

My 5-year mark prompted me to reflect on my entire experience…and how far I have come.

The benefit of neurofeedback by a closed-loop brain-computer interface was prominent when treating chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Being there for someone who is in need does more than you think.

Dr Noor Abuhadra discusses the various first-line treatment options for metastatic TNBC, highlighting the importance of PDL1 expression for immunotherapy and germline testing for targeted therapies like PARP inhibitors. Patient Shay Elkins shares her treatment journey, from her initial chemo and immunotherapy to surgical intervention, emphasizing the importance of a collaborative approach with her healthcare team and the supportive role of nursing staff.

One expert explained how patients with breast cancer have an increased risk for blood clots, even though one recently published survey determined that not many patients are aware of this.

Suzanne Somers, who was known for her role on “Three’s Company,” died the day before her 77th birthday.

A local art exhibit allowed expressive creativity on a unique canvas to raise breast cancer awareness.

I’ve been having a wonderful (well…maybe challenging is the right word) growing season this past year, learning how to be a better collaborator.

As drugs are getting “better and better,” breast surgery could be omitted, potentially offering improved results for patients with some invasive breast cancers.

The FDA granted fast track designation for a new inhibitor to treat patients with advanced or metastatic HR-positive, HER2-negative breast cancer.

Each October, we’re surrounded by the color pink as breast cancer awareness month gets into full swing. It can be a challenging time for many, but also a time of celebration.